Severe phenytoin intoxication in a subject homozygous for CYP2C9*3

被引:83
作者
Brandolese, R
Scordo, MG
Spina, E
Gusella, M
Padrini, R
机构
[1] Univ Padua, Dept Pharmacol & Anesthesiol, I-35131 Padua, Italy
[2] Univ Messina, Inst Pharmacol, Messina, Italy
[3] Conselve Hosp, Rehabil Serv, Padua, Italy
关键词
D O I
10.1067/mcp.2001.118868
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A 31-year-old woman who had a severe head injury was treated with oral phenytoin (100 mg 3 times a day) to prevent posttraumatic seizures. On day 10 of phenytoin treatment, 3 hours after the morning dose, the patient manifested neurologic signs compatible with phenytoin intoxication. Thus drug serum concentrations were monitored daily for 12 days. The elimination half-life was 103 hours, namely, about 5 times longer than the mean value generally quoted (22 hours). In the absence of any acquired predisposing factor for phenytoin toxicity, genetic mutations in the cytochrome P450 (CY-P) enzymes responsible for phenytoin metabolism (CYP2C9 and CYP2C19) were suspected. Genotyping revealed that the patient was homozygous for the C gamma P2C9*3 allele (C gamma P2C9*3/*3) and heterozygous for the C gamma P2C19*2 allele (C gamma P2C19*1/*2). In view of the markedly reduced metabolic activity of C gamma P2C*3 in comparison with the wild-type enzyme (about one fifth) and of the minor role of C gamma P2C19 in phenytoin metabolism, it is likely that C gamma P2C9*3 mutation was largely responsible for drug overdose.
引用
收藏
页码:391 / 394
页数:4
相关论文
共 16 条
  • [1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [2] Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
  • [3] DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
  • [4] DOLLERY C, 1999, THERAPEUTIC DRUGS, P110
  • [5] PHENYTOIN - PHARMACOGENETIC POLYMORPHISM OF 4'-HYDROXYLATION
    INABA, T
    [J]. PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) : 341 - 347
  • [6] Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele
    Kidd, RS
    Straughn, AB
    Meyer, MC
    Blaisdell, J
    Goldstein, JA
    Dalton, JT
    [J]. PHARMACOGENETICS, 1999, 9 (01): : 71 - 80
  • [7] The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
    Mamiya, K
    Ieiri, I
    Shimamoto, J
    Yukawa, E
    Imai, J
    Ninomiya, H
    Yamada, H
    Otsubo, K
    Higuchi, S
    Tashiro, N
    [J]. EPILEPSIA, 1998, 39 (12) : 1317 - 1323
  • [8] Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
    Miners, JO
    Birkett, DJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (06) : 525 - 538
  • [9] Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication
    Ninomiya, H
    Mamiya, K
    Matsuo, S
    Ieiri, I
    Higuchi, S
    Tashiro, N
    [J]. THERAPEUTIC DRUG MONITORING, 2000, 22 (02) : 230 - 232
  • [10] Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
    Odani, A
    Hashimoto, Y
    Otsuki, Y
    Uwai, Y
    Hattori, H
    Furusho, K
    Inui, K
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (03) : 287 - 292